Sangtech Lab's CellNet Blood Filtration Technology Wins Prestigious Awards

TAIPEI, TAIPEI CITY, TAIWAN, October 2, 2026 /CourierPR/ -- Sangtech Lab Inc. has achieved a significant milestone with its CellNet™ Blood Filtration Technology, which has won two prestigious awards in 2026. The technology, developed in collaboration with the Taiwan Textile Research Institute (TTRI), has been recognized with the Silver Award in the Energy & Climate Resiliency category at the 2026 Edison Awards and was selected as one of the year’s 100 leading innovations in the Process/Prototyping category of the 2026 R&D 100 Awards.

CellNet™ stands out for its innovative approach to blood filtration, utilizing a patented supercritical carbon dioxide (Supercritical CO₂) process to modify blood-filter fiber surfaces without the use of water or chemical solvents. This method addresses a long-standing challenge in conventional blood-filter manufacturing, which typically relies on substantial amounts of water and chemical solvents to make filter fibers blood-compatible. By eliminating these substances, CellNet™ not only maintains high filtration performance but also reduces concerns related to solvent residues and leaching, as well as significantly lowering water consumption.

The research findings for CellNet™ were presented at the 39th International Society of Blood Transfusion (ISBT) World Congress in Kuala Lumpur, Malaysia, in June 2026. The study, conducted in collaboration with National Taiwan University, National Taiwan University Hospital, and Taipei Medical University, was approved by the Institutional Review Board of National Taiwan University Hospital under IRB No. 202504050DINA. The research team included Professor Thierry Burnouf, an internationally recognized expert in transfusion science.

In terms of performance, CellNet™ has demonstrated remarkable capabilities in blood filtration. In fresh human whole-blood testing, the technology achieved the following results: - More than 99.99% leukocyte removal, meeting the most stringent leukoreduction standards. - 91-95% red blood cell recovery, helping to reduce blood-component loss during filtration. - 70-83% removal of storage microparticles associated with transfusion-related inflammatory reactions. - Stable blood quality after 35 days of refrigerated storage, with hemolysis remaining below the applicable regulatory limit.

These results underscore the technology's effectiveness in maintaining the quality and integrity of blood components, which is crucial for patient safety and treatment efficacy.

Moreover, CellNet™ offers significant environmental benefits. Its Supercritical CO₂ fiber surface treatment process uses no chemical solvents and no water, reducing the carbon footprint by approximately 90%. This environmental impact is achieved while maintaining advanced blood filtration performance, making it a sustainable solution for the medical industry.

The R&D 100 Awards, founded in 1963, recognize 100 of the world's most influential emerging technologies each year and are widely known as the "Oscars of Invention." Established in 1987, the Edison Awards recognize innovative products, services, and solutions based on their concept, value, and potential impact. In 2026, CellNet™ received the Silver Award in the Energy & Climate Resiliency category, highlighting its contribution to sustainable and resilient energy solutions.